MATEO ALAN
MATEO ALAN's purchase track record
MATEO ALAN has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/21/2025 | TXG | $446K | -25.1% | +31.2% | +7.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Transaction History
| TXG | ▲ Buy | Grant | 8,829 | $0 | 6/4/2026 | View on chart |
| TXG | ▲ Buy | Grant | 15,357 | $0 | 6/3/2025 | View on chart |
| TXG | ▲ Buy | Open Market | 40,000 | $446K | 2/21/2025 | View on chart |
| TXG | ▲ Buy | Grant | 21,691 | $0 | 7/31/2024 | View on chart |
| VEEV | ▼ Sell | Open Market | 3,391 | $681K | 4/23/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 5,000 | $0 | 4/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 995 | $229K | 4/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 2,558 | $589K | 4/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,944 | $0 | 4/1/2024 | View on chart |
| VEEV | ▼ Sell | Open Market | 910 | $186K | 1/17/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,943 | $0 | 1/1/2024 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 1,033 | $199K | 1/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 6,280 | $169K | 12/22/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 6,280 | $1.2M | 12/22/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,214 | $300K | 11/28/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,200 | $425K | 11/6/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 6,280 | $169K | 11/6/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 4,080 | $792K | 11/6/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 949 | $190K | 10/25/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 749 | $149K | 10/5/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 4,079 | $805K | 10/5/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,941 | $588K | 10/5/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 12,560 | $339K | 10/5/2023 | View on chart |
| VEEV | ▼ Sell | Open Market | 6,032 | $1.2M | 10/5/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,944 | $0 | 10/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 995 | $202K | 10/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,944 | $0 | 7/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 703 | $139K | 7/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,765 | $0 | 4/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 639 | $117K | 4/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,764 | $0 | 1/1/2023 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 680 | $110K | 1/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 25,120 | $678K | 12/7/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 3,180 | $523K | 12/7/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,800 | $469K | 12/7/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,800 | $471K | 12/7/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 3,880 | $635K | 12/7/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,400 | $399K | 12/7/2022 | View on chart |
| VEEV | ▼ Sell | Open Market | 1 | $169 | 12/7/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,765 | $0 | 10/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 791 | $130K | 10/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,765 | $0 | 7/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 639 | $130K | 7/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,090 | $0 | 4/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 395 | $86K | 4/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,090 | $0 | 1/1/2022 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 416 | $106K | 1/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 370 | $10K | 12/22/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,347 | $63K | 11/10/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,047 | $330K | 11/10/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 1,200 | $379K | 11/10/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 100 | $32K | 11/10/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,347 | $671K | 10/11/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,347 | $63K | 10/11/2021 | View on chart |
| VEEV | ▼ Sell | Tax Withholding | 558 | $160K | 10/1/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 1,090 | $0 | 10/1/2021 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 2,347 | $63K | 9/10/2021 | View on chart |
| VEEV | ▼ Sell | Open Market | 2,347 | $719K | 9/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center
10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.